Fair Value Calculator Fair Value Calculator
EN DE

2700 (2700) Fair Value & Analysis

Healthcare · Market cap HK$376M

2 2700 2700 · HK
PriceHK$0.5800
Fair ValueHK$0.1300
Upside-77.6%
Quality52/100
Watch 2700 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$0.1100 – HK$0.1500

Fair value as of: Jul 2, 2026

From 4 valuation models · updated today

Share price −6.5% over the past month.

Price vs Fair Value (12 months)

HK$0.6300 HK$0.4400 Fair Value HK$0.1300 Jun 2025 Jul 2026

12‑month range HK$0.4400 – HK$0.6300 · fair‑value band HK$0.1100 – HK$0.1500 · the HK$0.5800 price screens above the HK$0.1300 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2700 (2700) currently trades at HK$0.5800, while our model-based Fair Value estimate is HK$0.1300 — implying the stock looks roughly 77.6% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 2700 generated revenue of HK$54.3M at a net margin of -7.1%. Revenue declined 3.5% year over year. It earns a return on equity of -0.5%. The balance sheet holds a net cash position of HK$39.3M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$54.3M
Revenue growth (YoY) -3.5%
Net margin -7.1%
Return on equity -0.5%
Free cash flow −HK$4.8M FY2025
Operating margin -15.7%
More key figures
EPS (TTM) HK$-0.0100
Net cash HK$39.3M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2700 reported revenue of HK$54.3M in FY2025 versus HK$69.1M in FY2021, a compound −5.8%/yr. Reported net income was −HK$3.9M in FY2025.

Revenue −5.8%/yr
FY21 HK$69.1M
FY22 HK$47.2M
FY23 HK$48.8M
FY24 HK$53.0M
FY25 HK$54.3M
Net income
FY21 −HK$69.2M
FY22 −HK$13.2M
FY23 −HK$10.6M
FY24 −HK$807K
FY25 −HK$3.9M

Is 2700 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$95.75 R$123.65 +29%
Fresenius SE FSNUY $11.47 $8.55 -25%
5225 5225 8.71 MYR 4.87 MYR -44%
IHHHF IHHHF $1.71 $1.17 -32%
Tenet Healthcare Corporation THC $164.77 $280.85 +70%
Rede D'Or São Luiz S.A RDOR3 R$32.50 R$46.04 +42%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2700 (2700) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.1300 versus a price of HK$0.5800 — about −78% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 2700?
Our model-based fair value for 2700 is HK$0.1300 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.5800.
What is the quality score of 2700?
2700 has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 2700 (2700)?
2700 reported trailing-twelve-month revenue of about HK$54.3M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 2700?
The net profit margin of 2700 is about -7.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.